Ignite Creation Date:
2025-12-24 @ 6:57 PM
Ignite Modification Date:
2026-01-22 @ 6:31 AM
Study NCT ID:
NCT00946257
Status:
COMPLETED
Last Update Posted:
2017-06-01
First Post:
2009-07-23
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Subcutaneous Administration of Otelixizumab to T1DM Patients
Sponsor:
GlaxoSmithKline
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2009-07-08
Start Date Type:
ACTUAL
Primary Completion Date:
2011-08-01
Primary Completion Date Type:
ACTUAL
Completion Date:
2013-06-25
Completion Date Type:
ACTUAL
First Submit Date:
2009-07-23
First Submit QC Date:
None
Study First Post Date:
2009-07-24
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2017-05-31
Last Update Post Date:
2017-06-01
Last Update Post Date Type:
ACTUAL